Press Releases EXACT Therapeutics

Equities

EXTX

NO0010852213

Real-time Oslo Bors Other stock markets 10:45:00 2024-04-30 am EDT			5-day change	1st Jan Change
6.8 ^NOK	-.--%		-2.86%	-43.33%

Apr. 19	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EXACT Therapeutics : Successful placement of NOK 25 million share issue	Apr. 25	PU
Additional promising clinical data from EXACT Therapeutics' ongoing ACTIVATE study presented at AACR Annual Meeting	Apr. 10	AQ
EXACT Therapeutics to Present at 2024 American Association for Cancer Research (AACR) Annual Meeting	Mar. 06	AQ
EXACT Therapeutics AS - Share capital increase registered	Dec. 20	AQ
EXACT Therapeutics presenting at DNB Nordic Healthcare conference December 14	Dec. 14	AQ
EXACT Therapeutics : announces successful placement of NOK 25 million share issue	Dec. 01	PU
EXACT Therapeutics AS: Primary insider notices	Dec. 01	AQ
EXACT Therapeutics AS: Private placement successfully placed	Nov. 30	AQ
EXACT Therapeutics AS: Contemplated Private Placement	Nov. 30	AQ
EXACT Therapeutics receives regulatory approval to start recruitment of patients at Oslo University hospital	23-10-31	AQ
EXACT Therapeutics AS - Issuance of share options	23-10-16	AQ
EXACT Therapeutics CEO Dr Per Walday to participate in international Drug Delivery panel	23-10-12	AQ
EXACT Therapeutics : Interim Report 2023	23-09-28	PU
EXACT Therapeutics announces first half 2023 interim results	23-09-28	AQ
EXACT Therapeutics announces appointment of Caspar Foghsgaard as SVP Commercial & Business Development	23-09-27	AQ
EXACT Therapeutics announces positive clinical results from the ACTIVATE Phase I dose escalation	23-09-26	AQ
Invitation to first half results 2023 presentation of EXACT Therapeutics AS	23-09-19	AQ
EXACT Therapeutics : at the International Bubble Conference	23-09-08	PU
EXACT Therapeutics completed the dose escalation part of ACTIVATE study	23-08-07	AQ
EXACT Therapeutics receives regulatory approval to start the dose expansion part of ACTIVATE study	23-07-31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases EXACT Therapeutics

Equities

EXTX

NO0010852213

Press Releases

Filters